Stuart has spent the last 25 years in the Boston biotech scene and was most recently the CEO of immunology start-up QuantX Biosciences.  Among other roles, he was previously the CBO of vaccine company Affinivax until its sale to GSK, CFO and CBO of neuroscience company Praxis Medicines and was a co-founder of protein degradation company Kymera Therapeutics.  In addition to time at Amgen and Biogen, he has spent multiple stints as an Entrepreneur-in-Residence at Atlas Venture.  He holds a BS in chemistry from William and Mary, a PhD in organic chemistry from Yale, and an MBA in finance from the Wharton School.